Loading clinical trials...
Loading clinical trials...
The primary objective of this study is to establish noninferiority of efficacy of DWP14012 (40 mg once daily) based on Timing of Administration.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Daewoong Pharmaceutical Co. LTD.
Collaborators
NCT05890001 · Non-erosive Reflux Disease, Erosive Esophagitis
NCT05587309 · Erosive Esophagitis
NCT01499368 · Erosive Esophagitis
NCT05050188 · Erosive Esophagitis
NCT04124926 · Erosive Esophagitis
Hanyang University Medical Center
Seoul
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions